NasdaqCM:GNPX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Genprex, Inc. operates as a clinical-stage gene therapy company. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Genprex's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GNPX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-10.2%

GNPX

-4.0%

US Biotechs

-1.4%

US Market


1 Year Return

525.0%

GNPX

31.7%

US Biotechs

17.8%

US Market

Return vs Industry: GNPX exceeded the US Biotechs industry which returned 33.9% over the past year.

Return vs Market: GNPX exceeded the US Market which returned 18.5% over the past year.


Shareholder returns

GNPXIndustryMarket
7 Day-10.2%-4.0%-1.4%
30 Day-10.2%0.1%4.7%
90 Day-11.9%-3.5%8.2%
1 Year525.0%525.0%34.0%31.7%20.5%17.8%
3 Yearn/a18.7%12.8%42.2%32.7%
5 Yearn/a13.4%5.4%83.4%62.7%

Price Volatility Vs. Market

How volatile is Genprex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Genprex undervalued compared to its fair value and its price relative to the market?

5.12x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GNPX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GNPX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GNPX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: GNPX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GNPX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GNPX is overvalued based on its PB Ratio (5.1x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Genprex forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

24.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if GNPX's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if GNPX's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if GNPX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if GNPX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GNPX's Return on Equity is forecast to be high in 3 years time


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Genprex performed over the past 5 years?

-40.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GNPX is currently unprofitable.

Growing Profit Margin: GNPX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GNPX is unprofitable, and losses have increased over the past 5 years at a rate of 40.7% per year.

Accelerating Growth: Unable to compare GNPX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GNPX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: GNPX has a negative Return on Equity (-60.14%), as it is currently unprofitable.


Next Steps

Financial Health

How is Genprex's financial position?


Financial Position Analysis

Short Term Liabilities: GNPX's short term assets ($24.2M) exceed its short term liabilities ($239.8K).

Long Term Liabilities: GNPX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: GNPX is debt free.

Reducing Debt: GNPX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GNPX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: GNPX has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 50% each year.


Next Steps

Dividend

What is Genprex current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate GNPX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate GNPX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GNPX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GNPX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GNPX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average management tenure


CEO

John Varner (63 yo)

8.17yrs

Tenure

US$659,076

Compensation

Mr. John Rodney Varner is a co-founder of Genprex, Inc. and has been the Chief Executive Officer and Secretary of Genprex, Inc. since August 2012 and President since August 10, 2020, Chairman and Director ...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD659.08K) is about average for companies of similar size in the US market ($USD589.00K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
John Varner
Co, Founder8.17yrsUS$659.08k5.53%
$ 7.0m
Ryan Confer
Chief Financial Officer4.08yrsUS$1.00m0.19%
$ 239.0k
Michael Redman
Executive VP & COO0.58yrno datano data
Catherine Vaczy
Executive VP & Chief Strategy Officer0.58yrno datano data
Thomas Gallagher
Senior Vice President of Intellectual Property & Licensing0.083yrno datano data
Jack Roth
Chairman of Scientific & Medical Advisory Boardno datano data0%
$ 0

0.6yrs

Average Tenure

61yo

Average Age

Experienced Management: GNPX's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
John Varner
Co, Founder8.17yrsUS$659.08k5.53%
$ 7.0m
Jack Roth
Chairman of Scientific & Medical Advisory Boardno datano data0%
$ 0
Brent Longnecker
Independent Director0.58yrno data0%
$ 0
James Rothman
Strategic Advisor to the Board of Directors8.25yrsno datano data
Pasi Jänne
Member of Scientific & Medical Advisory Boardno datano datano data
Shu Kam Mok
Member of Scientific & Medical Advisory Boardno datano datano data
George Simon
Member of Scientific & Medical Advisory Boardno datano datano data
William Wilson
Independent Director0.58yrno data0%
$ 0
Jose Antonio Toscano
Independent Director0.58yrno data0%
$ 0

0.6yrs

Average Tenure

63.5yo

Average Age

Experienced Board: GNPX's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 145.4%.


Top Shareholders

Company Information

Genprex, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Genprex, Inc.
  • Ticker: GNPX
  • Exchange: NasdaqCM
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$126.330m
  • Shares outstanding: 38.87m
  • Website: https://www.genprex.com

Number of Employees


Location

  • Genprex, Inc.
  • Health Discovery Building
  • 1601 Trinity Street
  • Austin
  • Texas
  • 78712
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNPXNasdaqCM (Nasdaq Capital Market)YesVoting Common StockUSUSDMar 2018
2DEDB (Deutsche Boerse AG)YesVoting Common StockDEEURMar 2018

Biography

Genprex, Inc. operates as a clinical-stage gene therapy company. The company engages in developing technologies for cancer patients based upon a proprietary technology platform. Its platform technologies a ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 00:12
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.